TWI887826B - 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 - Google Patents

用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 Download PDF

Info

Publication number
TWI887826B
TWI887826B TW112141733A TW112141733A TWI887826B TW I887826 B TWI887826 B TW I887826B TW 112141733 A TW112141733 A TW 112141733A TW 112141733 A TW112141733 A TW 112141733A TW I887826 B TWI887826 B TW I887826B
Authority
TW
Taiwan
Prior art keywords
cancer
peak
compound
salt
ray powder
Prior art date
Application number
TW112141733A
Other languages
English (en)
Chinese (zh)
Other versions
TW202432100A (zh
Inventor
大衛 安德魯 寇堤斯
羅里 瑞奎爾 席爾登
吉斯蘭 庫曼克
Original Assignee
美商佩特拉製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商佩特拉製藥公司 filed Critical 美商佩特拉製藥公司
Publication of TW202432100A publication Critical patent/TW202432100A/zh
Application granted granted Critical
Publication of TWI887826B publication Critical patent/TWI887826B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112141733A 2022-11-02 2023-10-31 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑 TWI887826B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263421636P 2022-11-02 2022-11-02
US63/421,636 2022-11-02
US202263423879P 2022-11-09 2022-11-09
US63/423,879 2022-11-09

Publications (2)

Publication Number Publication Date
TW202432100A TW202432100A (zh) 2024-08-16
TWI887826B true TWI887826B (zh) 2025-06-21

Family

ID=88978500

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112141733A TWI887826B (zh) 2022-11-02 2023-10-31 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑

Country Status (8)

Country Link
EP (1) EP4612136A1 (enExample)
JP (1) JP7712994B2 (enExample)
KR (1) KR20250097960A (enExample)
CN (1) CN120476112A (enExample)
AU (1) AU2023373670A1 (enExample)
MX (1) MX2025005020A (enExample)
TW (1) TWI887826B (enExample)
WO (1) WO2024097205A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202964A1 (en) * 2020-04-03 2021-10-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA21528A1 (fr) * 1988-04-06 1989-12-31 Lipha Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres .
NZ538420A (en) * 2002-08-16 2007-06-29 Kinacia Pty Ltd Inhibition of phosphoinositide 3-kinase beta
US8519155B2 (en) * 2008-10-31 2013-08-27 C-A-I-R Biosciences Gmbh Choline and tromethamine salt of licofelone
EP3369730B1 (en) * 2012-11-05 2020-08-05 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
KR102485620B1 (ko) * 2017-03-03 2023-01-09 길리애드 사이언시즈, 인코포레이티드 Acc 억제제 및 그의 고체 형태를 제조하는 방법
AU2022268900B2 (en) * 2021-05-03 2024-12-19 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021202964A1 (en) * 2020-04-03 2021-10-07 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseases associated with p13k modulation

Also Published As

Publication number Publication date
MX2025005020A (es) 2025-08-01
KR20250097960A (ko) 2025-06-30
EP4612136A1 (en) 2025-09-10
AU2023373670A1 (en) 2025-05-15
TW202432100A (zh) 2024-08-16
JP7712994B2 (ja) 2025-07-24
JP2024067008A (ja) 2024-05-16
WO2024097205A1 (en) 2024-05-10
CN120476112A (zh) 2025-08-12

Similar Documents

Publication Publication Date Title
EP3573983B1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
EP3740206B1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6854496B2 (ja) 三環式ヘテロアリール基含有化合物
US9487529B2 (en) Macrocyclic compounds as ALK, FAK and JAK2 inhibitors
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN115677702B (zh) 三并环化合物及其药物组合物和应用
CN101687855A (zh) 酞嗪酮衍生物及其作为治疗癌症的药物的用途
CN118201930A (zh) Wee1蛋白激酶降解剂及其用途
JP2003519223A (ja) フェニルピペラジニル誘導体
CN118791505A (zh) 一种含肟结构的杂环化合物及其制备方法与用途
TWI887826B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
CN117143093A (zh) 一种蛋白降解剂及其制备方法和用途
CN113248497A (zh) 用作fgfr4抑制剂的稠环衍生物
CN118715224B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
TWI863667B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
CN115667241A (zh) TrkA抑制剂
WO2018054304A1 (zh) 呋喃并喹啉二酮类化合物及其医药用途
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
EP3986413A1 (en) Polymorphs of a macrocyclic kinase inhibitor
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
KR20160043116A (ko) 화합물의 제조 방법
EP4538273A1 (en) Compound and use thereof in preparation of bcl-xl inhibitor
CN116535423A (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用